236 related articles for article (PubMed ID: 15792738)
1. Mechanisms of action of newer antibiotics for Gram-positive pathogens.
Hancock RE
Lancet Infect Dis; 2005 Apr; 5(4):209-18. PubMed ID: 15792738
[TBL] [Abstract][Full Text] [Related]
2. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
[TBL] [Abstract][Full Text] [Related]
3. Gram-positive bacterial resistance. A challenge for the next millennium.
Bassetti M; Melica G; Cenderello G; Rosso R; Di Biagio A; Bassetti D
Panminerva Med; 2002 Sep; 44(3):179-84. PubMed ID: 12094131
[TBL] [Abstract][Full Text] [Related]
4. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
Scheinfeld N
J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
[TBL] [Abstract][Full Text] [Related]
5. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.
Johnson AP; Mushtaq S; Warner M; Livermore DM
Int J Antimicrob Agents; 2004 Oct; 24(4):315-9. PubMed ID: 15380254
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of quinupristin/dalfopristin, RP59500, against gram-positive clinical isolates.
Qadri SM; Ueno Y; Abu Mostafa FM; Halim M
Chemotherapy; 1997; 43(2):94-9. PubMed ID: 9084917
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
8. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.
Jones RN; Low DE; Pfaller MA
Diagn Microbiol Infect Dis; 1999 Feb; 33(2):101-12. PubMed ID: 10091033
[TBL] [Abstract][Full Text] [Related]
9. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
[TBL] [Abstract][Full Text] [Related]
10. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
Ross JE; Fritsche TR; Sader HS; Jones RN
Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570
[TBL] [Abstract][Full Text] [Related]
11. [Update on antibiotic resistance in Gram-positive bacteria].
Lozano C; Torres C
Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():2-8. PubMed ID: 28129816
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide.
Sader HS; Streit JM; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2004 Nov; 50(3):201-4. PubMed ID: 15541606
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging serious Gram-positive infections.
Menichetti F
Clin Microbiol Infect; 2005 May; 11 Suppl 3():22-8. PubMed ID: 15811021
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
Rybak MJ
Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
Anastasiou DM; Thorne GM; Luperchio SA; Alder JD
Int J Antimicrob Agents; 2006 Nov; 28(5):385-8. PubMed ID: 17046205
[TBL] [Abstract][Full Text] [Related]
17. Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.
Critchley IA; Draghi DC; Sahm DF; Thornsberry C; Jones ME; Karlowsky JA
J Antimicrob Chemother; 2003 Mar; 51(3):639-49. PubMed ID: 12615866
[TBL] [Abstract][Full Text] [Related]
18. Novel agents for resistant Gram-positive infections--a review.
Strahilevitz J; Rubinstein E
Int J Infect Dis; 2002 Mar; 6 Suppl 1():S38-46. PubMed ID: 12044288
[TBL] [Abstract][Full Text] [Related]
19. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009.
Dowzicky MJ; Chmelařová E
Int J Antimicrob Agents; 2011 Jun; 37(6):562-6. PubMed ID: 21497066
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and clinical relevance of microbial resistance determinants versus anti-Gram-positive agents.
Rossolini GM; Mantengoli E; Montagnani F; Pollini S
Curr Opin Microbiol; 2010 Oct; 13(5):582-8. PubMed ID: 20846900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
